Ciprofloxacin and Compulsory Licensing of Pharmaceutical Patents

DSpace/Manakin Repository

Ciprofloxacin and Compulsory Licensing of Pharmaceutical Patents

Citable link to this page

. . . . . .

Title: Ciprofloxacin and Compulsory Licensing of Pharmaceutical Patents
Author: Keller, Lauren
Citation: Ciprofloxacin and Compulsory Licensing of Pharmaceutical Patents (2002 Third Year Paper)
Full Text & Related Files:
Abstract: The recent threat of biological terrorism involving the Anthrax virus incited a debate about whether the United States government should use its powers under 28 USC §1498 to take a compulsory license on the drug ciprofloxacin in order to stockpile it. Negotiating a deal with Bayer allowed the United States to stockpile ciprofloxacin at a substantial discount while avoiding the negative consequences of issuing a compulsory license. Under 35 U.S.C. 1498, the United States government has the authority to issue a compulsory license; however, the government may not have the authority under the TRIPs agreement. In fact, under the interpretation of the TRIPs agreement that the United States has adopted in previous situations when other countries wanted to issue compulsory licenses on pharmaceuticals, the United States most likely would have violated TRIPs if it had issued a compulsory license for ciprofloxacin. Furthermore, the policy decision to have strong patent protection and to not have price controls on pharmaceuticals in the United States has led to the development of a very strong pharmaceutical industry that leads the world in the development of innovative drugs.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852122

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters